OKYO Pharma Ltd (NASDAQ:OKYO) plans to begin a phase II clinical trial for OK-101, targeting neuropathic corneal pain (NCP), in the third quarter.
In earlier studies, OK-101 showed significant pain relief for dry eye disease patients and reduced NCP in animal models. NCP is classified as an orphan disease by the National Organization for Rare Disorders.
The trial will be led by Dr Pedram Hamrah at Tufts Medical Center. He is a key expert in NCP and co-inventor of OK-101.
“I am looking forward to rigorously evaluating OK-101’s potential in treating pain symptoms in patients suffering from neuropathic corneal pain,” Hamrah said.
“We have designed an effective protocol to test our hypothesis in this patient population after productive FDA [US Food & Drug Administration] interactions and we will be closely overseeing the conduct of this trial at Tufts Medical Center.”